Display options
Cite
Buckon C, Sienko S, Bagley A, et al. Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?. PLoS Curr. 2016;8doi: 10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0.
Buckon, C., Sienko, S., Bagley, A., Sison-Williamson, M., Fowler, E., Staudt, L., Heberer, K., McDonald, C. M., & Sussman, M. (2016). Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?. PLoS currents, 8. https://doi.org/10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0
Buckon, Cathleen, et al. "Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?." PLoS currents vol. 8 (2016). doi: https://doi.org/10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0
Buckon C, Sienko S, Bagley A, Sison-Williamson M, Fowler E, Staudt L, Heberer K, McDonald CM, Sussman M. Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?. PLoS Curr. 2016 Jul 08;8. doi: 10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0. PMID: 27500011; PMCID: PMC4956479.
Copy Download .nbib Format: NLM
Share it on

PLoS Curr. 2016 Jul 08;8. doi: 10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0.

Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?.

PLoS currents

Cathleen Buckon, Susan Sienko, Anita Bagley, Mitell Sison-Williamson, Eileen Fowler, Loretta Staudt, Kent Heberer, Craig M McDonald, Michael Sussman

Affiliations

  1. Shriners Hospitals for Children-Portland, Portland, Oregon, USA.
  2. Shriners Hospitals for Children-Northern California, Sacramento, California, USA.
  3. Research and Evaluation Section, California Department of Public Health, Shriners Hospitals for Children-Northern California, Sacramento, California, USA.
  4. UCLA Department of Orthopaedic Surgery, Kameron Gait and Motion Analysis Laboratory, Los Angeles, California, USA.
  5. UCLA Department of Orthopaedic Surgery, Los Angeles, California, USA.
  6. Department of Physical Medicine and Rehabilitation, University of California-Davis, Shriners Hospitals for Children-Northern California, Sacramento, California, USA.
  7. Shriners Hospitals for Children-Portland, Portland, OR, USA.

PMID: 27500011 PMCID: PMC4956479 DOI: 10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0

Abstract

BACKGROUND: In the absence of a curative treatment for Duchenne Muscular Dystrophy (DMD), corticosteroid therapy (prednisone, deflazacort) has been adopted as the standard of care, as it slows the progression of muscle weakness and enables longer retention of functional mobility. The ongoing development of novel pharmacological agents that target the genetic defect underlying DMD offer hope for a significant alteration in disease progression; however, substantiation of therapeutic efficacy has proved challenging. Identifying functional outcomes sensitive to the early, subtle changes in muscle function has confounded clinical trials. Additionally, the alterations in disease progression secondary to corticosteroid therapy are not well described making it difficult to ascertain the benefits of novel agents, often taken concurrently with corticosteroids.

OBJECTIVE: The purpose of this study was to examine outcome responsiveness to corticosteroid therapy and age at the onset of a natural history study of ambulatory boys with DMD.

METHODS: Eighty-five ambulatory boys with DMD (mean age 93 mo, range 49 to 180 mo) were recruited into this study. Fifty participants were on corticosteroid therapy, while 33 were corticosteroid naïve at the baseline assessment. Within each treatment group boys were divided in two age groups, 4 to 7 years and 8 and greater years of age. The Biodex System 3 Pro isokinetic dynamometer was used to assess muscle strength. Motor skills were assessed using the upper two dimensions (standing/walking, running & jumping) of the Gross Motor Function Measure (GMFM 88) and Timed Motor Tests (TMTs) (10-meter run, sit to stand, supine to stand, climb 4-stairs). Two way analysis of variance and Pearson correlations were used for analysis.

RESULTS: A main effect for age was seen in select lower extremity muscle groups (hip flexors, knee extensors and ankle dorsiflexors), standing dimension skills, and all TMTs with significantly greater weakness and loss of motor skill ability seen in the older age group regardless of treatment group. Interaction effects were seen for the walking, running, and jumping dimension of the GMFM with the naïve boys scoring higher in the younger group and boys on corticosteroid therapy scoring higher in the older group. The TMT of climb 4-stairs demonstrated a significant treatment effect with the boys on corticosteroid therapy climbing stairs faster than those who were naïve, regardless of age. Examination of individual items within the upper level GMFM dimensions revealed select motor skills are more informative of disease progression than others; indicating their potential to be sensitive indicators of alterations in disease progression and intervention efficacy. Analysis of the relationship between muscle group strength and motor skill performance revealed differences in use patterns in the corticosteroid versus naïve boys.

CONCLUSION: Significant muscle weakness is apparent in young boys with DMD regardless of corticosteroid treatment; however, older boys on corticosteroid therapy tend to have greater retention of muscle strength and motor skill ability than those who are naive. Quantification of muscle strength via isokinetic dynamometry is feasible and sensitive to the variable rates of disease progression in lower extremity muscle groups, but possibly most informative are the subtle changes in the performance characteristics of select motor skills. Further analysis of longitudinal data from this study will explore the influence of corticosteroid therapy on muscle strength and further clarify its impact on motor performance.

References

  1. Muscle Nerve. 2007 Jan;35(1):36-42 - PubMed
  2. Dev Med Child Neurol. 2008 Jun;50(6):417-21 - PubMed
  3. Arch Neurol. 2003 Aug;60(8):1130-6 - PubMed
  4. Gait Posture. 2010 Jun;32(2):259-62 - PubMed
  5. Muscle Nerve. 2013 Sep;48(3):343-56 - PubMed
  6. Neuromuscul Disord. 2010 Nov;20(11):712-6 - PubMed
  7. Obes Rev. 2008 Mar;9(2):121-39 - PubMed
  8. Neuromuscul Disord. 2006 Jun;16(6):374-80 - PubMed
  9. Neuromuscul Disord. 2001 Mar;11(2):165-70 - PubMed
  10. Dev Med Child Neurol. 2006 Jun;48(6):540-4 - PubMed
  11. Pediatr Phys Ther. 2015 Winter;27(4):414-23 - PubMed
  12. Muscle Nerve. 2013 Apr;47(4):550-4 - PubMed
  13. Clin Investig (Lond). 2011 Sep;1(9):1217-1235 - PubMed
  14. Am J Phys Med Rehabil. 2002 Dec;81(12):906-12 - PubMed
  15. Neurology. 2014 Sep 9;83(11):974-80 - PubMed
  16. BMC Neurol. 2012 Sep 13;12:91 - PubMed
  17. Am J Phys Med Rehabil. 1995 Sep-Oct;74(5 Suppl):S70-92 - PubMed
  18. Muscle Nerve. 2013 Jul;48(1):55-67 - PubMed
  19. Neuromuscul Disord. 2009 Jul;19(7):458-61 - PubMed
  20. Acta Paediatr. 2008 May;97(5):602-7 - PubMed
  21. Muscle Nerve. 1982 Apr;5(4):291-301 - PubMed
  22. Curr Treat Options Neurol. 2008 Mar;10(2):86-93 - PubMed
  23. Neuromuscul Disord. 2005 Jul;15(7):463-70 - PubMed
  24. Neuromuscul Disord. 2012 Jan;22(1):16-25 - PubMed
  25. Dev Med Child Neurol. 1998 Oct;40(10):693-701 - PubMed
  26. Dev Med Child Neurol. 2013 Nov;55(11):1046-52 - PubMed
  27. Arq Neuropsiquiatr. 2007 Jun;65(2A):245-50 - PubMed
  28. N Engl J Med. 1989 Jun 15;320(24):1592-7 - PubMed

Publication Types